Taj Pharmaceuticals, a global pharmaceutical manufacturer with WHO-GMP, PIC/S, ISO 9001:2018, and GLP compliance, continues to align its quality systems with the evolving regulatory standards of ASEAN markets. Among these, Myanmar FDA (Food and Drug Administration) is one of the most stringent regulatory authorities in the region, mandating complete adherence to ACTD, GMP compliance, and an online e-submission model.

This article provides an in-depth view of:

  1. Taj Pharma’s Quality Assurance (QA) competency and its role in global dossier development
  2. Myanmar FDA New Registration Guidelines (2022 Online Registration System)
  3. Myanmar FDA e-Submission Guidelines (2021–2022 Circular)
  4. Complete ACTD Module-wise Requirements for Myanmar

Part I: Taj Pharma QA Team – Backbone of Global Compliance

At Taj Pharma, Quality Assurance is the central pillar ensuring that every product delivered to international markets meets the standards of Safety, Quality, and Efficacy (SQE). The QA division consists of:

  • Regulatory QA
  • Documentation & Compliance
  • In-Process QA
  • Validation & Qualification QA
  • Quality Systems Management
  • GMP Audit & Vendor Qualification Unit
  • Export Regulatory Support Team

These teams work in complete synergy to ensure compliance with international regulatory frameworks including:

  • WHO (World Health Organization)
  • PIC/S (Pharmaceutical Inspection Co-operation Scheme)
  • US FDA, EMA, MHRA expectations (as applicable)
  • ASEAN CTD (Common Technical Dossier)
  • GCC, African MoH, LATAM, CIS, and SEA regulatory systems

1. Documentation Strength & Regulatory Excellence

Taj Pharma’s QA team excels in preparing:

  • ACTD dossiers
  • CTD modules
  • GMP and CPP support documentation
  • CoA, stability data, validation reports
  • Product quality reviews (PQR)
  • Process validation & cleaning validation reports
  • Bioequivalence and comparative dissolution data

This organizational structure allows Taj Pharma to maintain high-quality dossier submissions for heavily regulated ASEAN markets like Myanmar, Philippines, Vietnam, and Cambodia.


Part II: Myanmar FDA Registration Guidelines – 2022 Online Registration System

Myanmar FDA launched a new online registration platform in 2022 to streamline the licensing of pharmaceutical products. Under this system:

  • All dossiers must be uploaded digitally
  • Each PDF file must not exceed 5 MB
  • Files must be single-document-per-heading, strictly as per ACTD format
  • Stability data & laboratory samples submission requirements are strengthened

Below is the complete guideline.


1. Administrative Documents (ACTD Part I)

All files ≤ 5MB per PDF

(1) Letter of Authorization (LOA)

Power of Attorney/Authorization letter by manufacturer.

(2) Manufacturing License / Pharmaceutical Industry License

Issued by the home country authority.

(3) Certificate of Pharmaceutical Product (CPP)

According to WHO format—must be current and legalised.

(4) GMP Certificate (Country of Origin)

Issued by the competent regulatory authority.

(5) PIC/S GMP Certificate / Latest GMP Inspection Report & CAPA

Must be within the last 2 years; CAPA must be in English.

(6) List of Other Exporting Countries

(7) Site Master File (SMF)

Required unless previously submitted in last 2 years.

(8) Package Insert

(9) Product Packaging Artwork

Primary & secondary packaging (high-resolution image)


2. Quality (Drug Substance) – ACTD Part II (S Module)

S Module – Drug Substance

S.1 General Information

S1.1 Nomenclature

  • INN
  • CAS
  • Chemical names
  • Other identifiers

S1.2 Structure

  • Structural formula
  • Molecular formula
  • Molecular weight
  • Stereochemistry

S1.3 General Properties

  • Physico-chemical characteristics
  • Solubility
  • Polymorphism
  • Biological activity (biotech)

S2 Manufacture

S2.1 Manufacturer(s)

Full name, address, responsibilities.

S3.1 Structure Elucidation

  • Spectral analysis (IR, NMR, MS)
  • Analytical confirmations

S7 Stability

  • Literature-based stability
  • Shelf life justification

(All S-module files as individual PDFs)


3. Quality (Drug Product) – ACTD Part II (P Module)

P1: Description & Composition

Description

  • Dosage form
  • Characteristics
  • Diluent details
  • Container/closure system

Composition

  • Name & quantities of all ingredients
  • Function (API, excipient, stabilizer)

P2.2 Components of Drug Product

P2.2.1 Active Ingredient

  • Literature data on API

P2.3 Finished Product

P2.3.2 Overages

  • Justification (if any)

Physicochemical and Biological Properties

  • pH
  • Dissolution
  • Other relevant performance parameters

P2.4 Manufacturing Process Development

  • Rationale
  • Optimization steps

P2.5 Container Closure System

  • Suitability for storage, transport
  • Moisture protection

P2.6 Microbiological Attributes

  • Bioburden
  • Sterility (if applicable)

P3 Manufacturing Information

P3.1 Batch Formula

  • Quantities of all components

P3.2 Manufacturing Process & Controls

  • Flowchart
  • Step-by-step process

P3.3 Critical Steps & Intermediates

  • Control strategy

P3.4 Process Validation

  • Validation summary
  • Critical assay validations

P4 Control of Excipients

P4.2 Analytical Procedures

  • Compendial references
  • Where applicable

P5 Control of Finished Product

P5.1 Specifications

  • Physical
  • Chemical
  • Microbiological

P5.2 Analytical Procedures

P5.3 Validation of Analytical Methods

  • Non-compendial methods
  • Compendial method verification: accuracy & precision

P5.4 Batch Analysis

  • 3 batches (commercial scale preferred)

P5.5 Impurity Characterisation

P5.6 Specification Justification


P6 Container Closure System

  • Primary & secondary packaging
  • Desiccant details
  • Dimensions
  • Labeling

P7 Stability

  • 3 complete stability batches
  • Zone IVb (30°C/75% RH) for Myanmar
  • Post-approval stability commitment

P8 Product Interchangeability (Generic Only)

For New Molecules in Myanmar

  • In vitro comparative dissolution
  • In vivo BE study (if required)

Part III: Myanmar FDA 2021–2022 E-Submission Guidelines

Myanmar FDA implemented additional rules under the 2021–22 circular for digital submissions and sample handling.


1. Brand Name Checking Discontinued

Applicants must self-check brand name conflicts.
FDA will not provide brand name verification support.


2. Sample Import Permit (IP)

  • Issued by FDA
  • Valid for 6 months
  • Import only the exact quantity specified
  • Submit samples within 3 weeks of arrival
  • Original CoA mandatory (photocopies not accepted)

3. ACTD + ACTR Submission Mandatory

Upload to FDA e-submission portal:

  • Part I – Administrative Documents
  • Part II – Quality Documents
  • Clinical & Non-Clinical (for new molecules & biologicals)

4. Shelf Life Requirement for Samples

  • Minimum 1 year and 6 months remaining shelf life
  • If less, samples will be rejected without appeal

5. Complete Documents Must Be Uploaded Only After Sample Submission

  • Dossier upload follows sample submission
  • No partial submissions

6. Only One Opportunity for Query Response

  • One chance to correct deficiencies
  • Time allowed: 1 month

After this, application is rejected.


7. System Auto-Rejection Clause

If submission is incomplete after one month → rejection.


8. Preview Approval & Fee Payment

  • Upon meeting criteria, FDA issues a Preview Notice
  • Registration fees must be paid within 3 months
  • Failure → automatic cancellation

9. Rejection Letter Issued for Non-Compliance

Reasons include:

  • Failed laboratory results
  • Incomplete or incorrect documentation
  • Non-compliance with defined technical criteria

10. Online Registration Certificate Issuance

  • Final certificate is issued digitally via portal
  • No physical paper certificate issued

Taj Pharma’s integrated QA framework is built to support stringent global regulatory requirements, ensuring seamless access to international markets such as Myanmar. The Myanmar FDA’s 2022 Online Registration System and updated e-Submission requirements demand strict ACTD compliance, complete stability data, validated analytical procedures, accurate administrative documentation, and a robust quality management system.

With strong QA capabilities, validated manufacturing processes, PIC/S-aligned documentation, and professional regulatory support, Taj Pharmaceuticals is fully equipped to meet Myanmar FDA’s highest expectations, ensuring faster approvals, sustainable supply, and superior quality medicines for the Myanmar healthcare system.